Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6004 + Gemcitabine in Advanced Solid Tumors
NCT02240238Phase 2Completed
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- May 2014
- Primary completion
- May 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of NK211 in solid tumor, squamous cell carcinoma of the lung (SCCL), biliary tract cancer (BTC), bladder cancer, sponsored by NanoCarrier Co., Ltd.. Started May 2014; status: completed.
02
Drugs
NK211
03
Conditions
solid tumorsquamous cell carcinoma of the lung (SCCL)biliary tract cancer (BTC)bladder cancer
Beyond the preview
Go deeper on NCT02240238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240238.